| Abbreviation | Definition |
|---|---|
| AC | Anterior Chamber |
| ANZMUSC | Australian and New Zealand Musculoskeletal Clinical Trials Network |
| b/tsDMARDs | Either biologic DMARDs or targeted synthetic DMARDs |
| bDMARD | Biologic disease-modifying antirheumatic drug |
| CHAQ | Childhood Health Assessment Questionnaire |
| CI | Confidence interval |
| csDMARD | Conventional synthetic disease-modifying antirheumatic drug |
| DAS28 | Disease Activity Score in 28 joints |
| DMARD | Disease-modifying antirheumatic drug |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| IV | Intravenous |
| JIA | Juvenile idiopathic arthritis |
| MD | Mean difference |
| mSvdH | Modified Sharp van der Heijde |
| NHMRC | National Health and Medical Research Council |
| NNTB | Number needed to treat for an additional beneficial outcome |
| NNTH | Number needed to treat for an additional harmful outcome |
| NSAID | Non-steroidal anti-inflammatory drug |
| PBS | Pharmaceutical Benefits Scheme |
| PICO | Participant Intervention Comparison Outcomes |
| RCT | Randomised controlled trial |
| RR | Risk ratio |
| TGA | Therapeutic Goods Administration |
| TNF | Tumour necrosis factor |
| tsDMARD | Targeted synthetic disease-modifying antirheumatic drug |